Biotechnology company focused on immunotherapy research and development

2seventy Bio

Biotechnology company specializing in genome editing and cell therapy

Caribou

Biotechnology company focused on gene editing and cell therapy

Precision BioSciences

Pharmaceutical company with a focus on developing therapies for various diseases including cancer and autoimmune conditions

Abbvie

Biotechnology company known for its innovative therapies in oncology and immunology

Amgen

Pharmaceutical company focusing on cancer, cardiovascular, and immunology therapies

Bristol Myers Squibb

Global pharmaceutical company with a diverse portfolio of pharmaceuticals, vaccines, and consumer healthcare products

GlaxoSmithKline

Multinational corporation with a focus on pharmaceuticals, medical devices, and consumer goods

Johnson & Johnson

Global pharmaceutical company known for its innovative medicines and vaccines

Pfizer

Global healthcare company with a focus on innovative pharmaceuticals, eye care, and generic medicines

Novartis

Arcellx, Inc. is a biotechnology company focused on developing innovative immunotherapies for patients with cancer and other incurable diseases. The company's lead products include anitocabtagene autoleucel and ACLX-001, both of which are in clinical trials for the treatment of multiple myeloma and other related conditions.

We are a clinical-stage biotechnology company reimagining cell therapy through the development of innovative immunotherapies.


Kite Pharma

JVC Investment Partners

LG Technology Ventures

Solasta Ventures

Samsara BioCapital

Novo Holdings

Adage Capital Management

Asymmetry Ventures

CaaS Capital Management

Cambrian Biopharma

CAM Capital

Clough Capital Partners

Soleus Capital

SR One

Surveyor Capital

Suvretta Capital Management

Takeda Ventures

Terra Magnum Capital Partners (""""TMCP"""")""

Arcellx

Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company's lead ddCAR product candidate is CART-ddBCMA, which is in phase 1 clinical trial for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM). It is also developing ACLX-001, an immunotherapeutic combination composed of ARC-T cells and bi-valent SparX proteins targeting BCMA to treat r/r MM; ACLX-002 and ACLX-003 for treating r/r acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS); and other AML/MDS product candidates, as well as solid tumor programs. The company was formerly known as Encarta Therapeutics, Inc. and changed its name to Arcellx, Inc. in January 2016. Arcellx, Inc. was incorporated in 2014 and is headquartered in Gaithersburg, Maryland.

Arcellx, Inc.

industry_trends_dossier

news_impact_assignment_basic

key_people

company_dossier

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

network

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

events

strategic_challenges

network_mapping

industry_trends

transactions_dossier

strategic_challenges_dossier

financial_statements

network_onboarding

company_summary

signals

regulatory_analysis

industry_analysis

swot_dossier

competition_analysis

financial_legal_advisories

merger_acquisitions

swot_analysis

financial_analysis

news_advanced

purchaser_profile

news_impact_assignment_advanced

news_processing_advanced

peers

news_basic

valuation

customer_profile

NASDAQ:ACLX

Arcellx, Inc.

Last Close

67.48

30/08 20:00

Market Cap

3.07B

Beta: -

Volume Today

327.10K

Avg: 484.45K

PE Ratio

−24.88

PFCF: 30.94